Skip to content
value.today

ZeroStack Corp.

ZSTK
$51 Mmarket cap on Oct 30, 2026+365.9% since Jan 2024
Compare
World rank
#21,187
Revenue
$36 M
For year ending December-2025
Net income
$-120 M
-335.6% margin
SEC filing
Employees
21
As of December 31, 2025
value.today research

ZeroStack Corp. in brief

ZeroStack Corp. is a listed company in the Pharmaceutical industry, based in the USA. Its market value was $51 M on 30 October 2026, which makes it the 21,187th largest listed company in the world and the 3,844th largest in the USA on this site. In the year to December 2025 it had sales of $36 M and a net loss of $120 M. It employs about 21 people. Its shares trade under the symbol ZSTK (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About ZeroStack Corp.

ZeroStack Corp. (formerly Flora Growth Corp.) was incorporated as Flora Growth Corp. on March 13, 2019, under the laws of the Province of Ontario. On January 29, 2026, the Company changed its corporate name from "Flora Growth Corp." to "ZeroStack Corp." and changed its Nasdaq ticker from "FLGC" to "ZSTK". We are a decentralized AI treasury and AI-focused asset management company that is investing in the future of AI. Our first AI-oriented project is through strategic ownership in 0G Tokens (as defined below). The Company is a global pharmaceutical distributor through its wholly owned subsidiary Phatebo GmbH.

ZeroStack Corp. timeline

5 events, 2019–2026
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 🔔
    Initial public offering as Flora Growth Corp.
    Final prospectus filed with the SEC on 12 May 2021; shares registered for exchange trading on 10 May 2021.
  6. 2023
  7. 💰
    Record revenue of $76 million
    FY2023, the highest of the 5 years on record.
  8. 2026
  9. ✎
    Renamed ZeroStack Corp.
    Formerly Flora Growth Corp..

Events of ZeroStack Corp. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$30 M$60 M$91 M$121 M2023202420252026

World rank over time

▲ up 931 places since 2022
2022-01-07: #22157#22,15720222022-12-25: #28909#28,90920222023-07-30: #29951#29,95120232024-01-05: #31061#31,06120242026-10-30: #21226#21,2262026

Rank in USA: #4,321 (Jan 2022) · #5,242 (Dec 2022) · #5,252 (Jul 2023) · #4,499 (Jan 2024) · #3,848 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
1.3×
Price / book
0.7×
Free cash flow yield
-17.2%
Net margin (TTM)
-444.3%
Operating margin
-433.4%
Return on equity
-252.1%
Liabilities / assets
45.8%
Net debt
$48M
Revenue growth
-0.5%
R&D / revenue
1.2%
Revenue per employee
$1.7 M
Profit per employee
$-5.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue $9M, net income $-21M$9MFY21Fiscal year ending Dec 2022: revenue $33M, net income $-52M$33MFY22Fiscal year ending Dec 2023: revenue $76M, net income $-57M$76MFY23Fiscal year ending Dec 2024: revenue $36M, net income $-16M$36MFY24Fiscal year ending Dec 2025: revenue $36M, net income $-120M$36MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$36M-0.5%$-155M$-120M-335.6%
Dec 2024$36M-52.9%$-9M$-16M-44.4%
Dec 2023$76M+127.8%$-50M$-57M-75.0%
Dec 2022$33M+271.9%$-47M$-52M-156.9%
Dec 2021$9M—$-19M$-21M-237.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M$0M$-9M$-43.49—
Dec 2024$-5M$0M$-5M$-50.02—
Dec 2023$-8M$0M$-9M$-7.75—
Dec 2022$-16M$1M$-17M$-13.68—
Dec 2021$-21M$4M$-25M——

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$40M
Net income, trailing 12 months
$-178M
RevenueNet income
Three months to Sep 2024: revenue $7M, net income $-4M$7MSep ’24Three months to Dec 2024 (from the annual report): revenue $8M, net income $-6M$8MDec ’24Three months to Mar 2025: revenue $7M, net income $-1M$7MMar ’25Three months to Jun 2025: revenue $10M, net income $-2M$10MJun ’25Three months to Sep 2025: revenue $10M, net income $-7M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $-110M$9MDec ’25Three months to Mar 2026: revenue $7M, net income $-37M$7MMar ’26Three months to Jun 2026: revenue $14M, net income $-25M$14MJun ’26

Latest quarter to Jun 2026: revenue $14M (+40.7% on a year earlier), net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of ZeroStack Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
$36 M
Operating income
$-155 M
Net income
$-120 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$130 M
Total liabilities
$60 M
Total equity
$71 M

As of December-2025

Top 17 institutional investors in ZeroStack Corp.#

As of Sep 30, 2026
17 institutions held 366,272 shares (about 2.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.1%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in ZeroStack Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
1MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.125,886New0.72%$1 MNov 16, 2026
2Vanguard Capital Management LLC92,907New0.53%$0 MNov 13, 2026
3Geode Capital Management, LLC49,399New0.28%$0 MNov 6, 2026
4Vanguard Fiduciary Trust Co38,323New0.22%$0 MNov 13, 2026
5Bolton Securities Corporation26,923New0.15%$0 MNov 12, 2026
6State Street Corp13,437New0.08%$0 MNov 12, 2026
7Northern Trust Corp11,281New0.06%$0 MNov 16, 2026
8UBS Group AG4,169New0.02%$0 MNov 10, 2026
9Citigroup Inc2,930New0.02%$0 MNov 4, 2026
10Tower Research Capital LLC (TRC)948New0.01%$0 MNov 16, 2026
11Caitong International Asset Management Co., Ltd15New0.00%$0 MOct 29, 2026
12Royal Bank Of Canada12New0.00%$0 MNov 16, 2026
13Northwestern Mutual Wealth Management Co12New0.00%$0 MNov 13, 2026
14Osaic Holdings, Inc.12New0.00%$0 MNov 12, 2026
15SBI Securities Co., Ltd.10New0.00%$0 MOct 22, 2026
16Morgan Stanley7New0.00%$0 MNov 13, 2026
17Key Financial Inc1New0.00%$0 MNov 2, 2026

Insider trading at ZeroStack Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$3.5 M
1 purchase, 1 insider
Sold, 12 months
$8 K
1 sale, 1 insider
Net, 12 months
$3.4 M
open market only
Insiders on file
17
since
$3.5 M-$8 K$0Apr 2024: bought $1000 K (1 trades), sold $0 (0 trades)Apr 24Sep 2024: bought $31 K (5 trades), sold $0 (0 trades)SepJul 2026: bought $3.5 M (1 trades), sold $0 (0 trades)JulAug 2026: bought $0 (0 trades), sold $8 K (1 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
ZeroStack Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Rudy RongPresidentSell-1,000$7.570$8 K0Form 4
filed Michael HeinrichExecutive Chairman, DirectorBuyindirect+4.61 M$0.750$3.5 M4.61 MForm 4
filed Daniel Reis-FariaCEO, DirectorExercise of in-the-money derivative+5.95 M——5.95 MForm 4
filed Edward WooDirectorGrant or award+50,000——134,698Form 4
filed Clifford StarkeCEO, DirectorGrant or award+900,000——906,846Form 4
filed Sammy DorfExecutive Chairman, DirectorGrant or award+250,000——250,000Form 4
filed Clifford StarkeCEO, DirectorBuy+6,795$0.950$6 K6,846Form 4
filed Harold WolkinDirectorBuy+5,000$0.960$5 K5,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: ZeroStack Corp.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
53,137
5.1% of shares · 2.84 days to cover
Buybacks, Q4 2023
$0M
Q4 2023
Shares sold short, last 24 reportsAll stocks →
ZeroStack Corp. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q4 2022Q4 2022$0M
Q3 2022Q3 2023$0M

Trading halts

  • 2026-08-25 13:38 UTC, code LUDP, resumed 13:43 UTC
  • 2026-08-21 14:44 UTC, code LUDP, resumed 14:54 UTC
  • 2026-08-20 13:32 UTC, code LUDP, resumed 13:46 UTC
  • 2026-08-19 15:50 UTC, code LUDP, resumed 16:00 UTC
  • 2026-08-19 15:45 UTC, code LUDP, resumed 15:50 UTC

Fails to deliver

  • : 840 shares at $2.93
  • : 113 shares at $4.00
  • : 116 shares at $4.22
  • : 4,345 shares at $4.05
  • : 156 shares at $4.64

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

ZeroStack Corp. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in financial health (2 of 4), weakest in growth (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median1.3×Price to sales 1.3× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%-17.2%Free cash flow is -17.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 4
    • ✗Revenue grew in the newest year-0.5%Revenue down 0.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years2.2%2.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median2.2%2.2% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-43.49 vs -50.02Diluted EPS -43.49 in fiscal 2025 against -50.02 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$120 MNet income -$120 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-433.4%-433.4% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-319.0%-319.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-433.4%-433.4% in fiscal 2025 against -141.4% in 2022.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities1.0×Current ratio 1.01 at the end of fiscal 2025.
    • ✓Debt below equity0.8×Debt to equity 0.76 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-6.11Z-score -6.11 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from ZeroStack Corp.'s statements, beside the median of Pharmaceutical.

ZeroStack Corp.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-433.4%1.8%
Net margin-335.6%-1.5%
Return on equity-319.0%-0.9%
Revenue growth, 3 years a year2.2%2.5%
Revenue growth-0.5%7.3%
Debt to equity0.76×0.66×

1of 9on the Piotroski tests of financial strength

  • Revenue fell 0.5% against the year before.
  • Net loss of $120 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$9 million.

ZeroStack Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

ZeroStack Corp.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue3636r7633r9.00.1—
Cost of revenue3434r5820r6.6r0.0—
Gross profit1.62.2r1813r2.40.1—
Research and development—0.40.10.4r0.10.1—
Selling, general and administrative————4.51.4—
General and administrative1.41.9r1.63.3r0.9——
Operating expenses15611r6860r21——
Operating income−155−8.9r−50−47r−19——
Interest expense and finance costs————0.10.0—
Net interest income−0.2−0.2−0.10.1r0.0——
Income before tax−115−9.3r−48−48r−21−14−2.8
Income tax0.10.0r−1.6−1.4r−0.100
Income from continuing operations−115−9.3r−47−47———
Income from discontinued operations−4.3−6.6r−9.7−5.9———
Net income including minority interests−120−16−56−53r21r−14—
Minority interests' share of net income—00.7−0.2———
Net income attributable to shareholders—−16−57−52r−21——
Earnings per share, basic-43.49-50.02r-7.75-13.68-0.48-0.47—
Earnings per share, diluted-43.49-50.02r-7.75-13.68———
Shares, weighted average (basic)0.00.0r0.00.00.00.0—
Shares, weighted average (diluted)0.00.0r0.00.0———
Balance sheet
Cash and cash equivalents5.65.2r4.48.9r38160.1
Short-term investments————2.70—
Receivables0.81.6r4.05.3r5.30.9—
Inventory1.92.2r8.58.7r3.0r0.5—
Other current assets0.30.0r1.40.8r1.7——
Current assets8.72021314818—
Property, plant and equipment0.10.1r0.81.2r3.80.4—
Right-of-use (leased) assets0.40.2r0.42.1r1.20.3—
Goodwill—2.002320r0.4r—
Other intangible assets—2.70.918r9.70.7—
Long-term investments—000.7———
Total assets1302624818519—
Accounts payable2.33.6r5.17.8r2.4r1.8—
Debt due within a year2.72.11.91.10.0——
Current liabilities8.61916176.12.7—
Long-term debt510—————
Lease liabilities (non-current)0.30.1r0.91.6r0.9r0.1—
Total liabilities602217258.53.2—
Retained earnings−278−158−143−91−39−17—
Shareholders' equity714.56.45777——
Minority interests——0−0.4−0.2−0.1—
Total equity714.56.4567716−1.3
Total liabilities and equity1302624818519—
Shares outstanding1.00.5r8.96.8r0.1——
Cash-flow statement
Depreciation and amortization0.60.82.52.60.5r0.1—
Share-based compensation1.22.81.63.41.3——
Cash from operating activities−8.7−5.0−8.4−16−21r−8.4—
Capital expenditure−0.1−0.1−0.2−1.3−4.0r0—
Acquisitions, net of cash acquired−0.5−0.10−15−8.1——
Cash from investing activities−3.50.2−0.2−16−15−2.2—
Debt issued2.88.41.00.200.0—
Debt repaid−2.4−8.1−0.2−0.2−0.3r−1.0—
Shares issued167.52.75.0r43——
Shares bought back——0−0.30——
Cash from financing activities116.53.24.458r26—
Exchange-rate effect on cash————−0.80.2—
Change in cash0.41.7−4.6−2822r15—
Report10-K10-K10-K10-K10-K20-F/A20-F/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where ZeroStack Corp. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

ZeroStack Corp.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇩🇪 Germany1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at ZeroStack Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Auditor changed 1 · Acquisition or sale completed 4 · Directors and officers 11 · Material agreement 12 · Agreement ended 4 · New debt 1 · Unregistered share sale 7 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 3

ZeroStack Corp.: events reported to the SEC
FiledWhat happenedFiling
Auditor changed8-K
Material agreement8-K
Directors and officersMaterial agreementAgreement ended8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share sale8-K
Acquisition or sale completed8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Material agreementAgreement endedUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Directors and officers8-K
Material agreementAgreement endedUnregistered share sale8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Material agreementUnregistered share sale8-K
Acquisition or sale completedDirectors and officersMaterial agreementNew debtUnregistered share sale8-K
Material agreement8-K
Delisting noticeDirectors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Acquisition or sale completedMaterial agreementUnregistered share sale8-K
Directors and officers8-K
Material agreement8-K
Material agreement8-K
Agreement ended8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of ZeroStack Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$1.0 BPrivate placement after listing$1 billion or more2equity, optionsSEC
Jul 2026$92 MPrivate placement after listing$50 to $250 million24equitySEC
Sep 2025$25 MPrivate placement after listing$10 to $50 million18optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How ZeroStack Corp. compares in Pharmaceutical

  • Market cap$51 M · higher than 13% of 393
  • Revenue$36 M · higher than 12% of 324
  • Net margin-444.3% · higher than 2% of 313
  • Revenue growth-0.5% · higher than 25% of 107
  • Price / sales1.3× · lower than 77% of 219
  • Price / book0.7× · lower than 91% of 207
  • FCF yield-17.2% · higher than 19% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
ZeroStack Corp.🇺🇸$51 M—-444.3%-0.5%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at ZeroStack Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show ZeroStack Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about ZeroStack Corp.? Suggest a correction